儿童一线抗结核治疗中乙胺丁醇的药代动力学与剂量优化:个体患者数据荟萃分析
该研究基于3项研究的220名儿童数据,采用非线性混合效应模型分析乙胺丁醇药代动力学并模拟优化剂量。模拟显示体重<25kg儿童在现行WHO推荐剂量下暴露量低于目标暴露分布,优化体重带剂量可使约40.5%患者剂量增加,另5%可能获益。结论支持修订儿童乙胺丁醇剂量指南。
要点
- 体重<25kg儿童按现行WHO剂量乙胺丁醇暴露低于目标暴露分布。
- 优化体重带剂量可使约40.5%患者剂量增加,另5%可能获益。
- 建议修订儿童乙胺丁醇剂量指南以保证全 weight band adequate exposure。
核心结论
- 本个体患者数据荟萃分析支持修订现行儿童乙胺丁醇剂量指南,以确保所有儿科体重带获得 adequate 药物暴露。
研究设计与样本
- 研究纳入3项研究的220名儿童(0.2-15岁;体重3.6和43.0 kg),共1085个血浆乙胺丁醇浓度,采用非线性混合效应模型分析。
主要发现
- 体重效应被纳入清除率、隔室间清除率及中央和外周分布容积,年龄通过成熟函数影响清除率。
- 模拟显示体重<25 kg儿童在现行WHO推荐剂量下乙胺丁醇中位暴露低于目标暴露分布(AUC 13.8-17.7 mg·h/L)。
- 优化体重带剂量可使约40.5%患者剂量增加,另5%可能获益。
关键数值与推荐
- 目标暴露分布为AUC 13.8-17.7 mg·h/L,基于成人临床试验先前建立。
- 现行WHO推荐剂量下体重<25 kg儿童中位暴露低于目标暴露分布。
临床怎么用
- 临床可参考优化体重带剂量方案调整儿童乙胺丁醇剂量,但需权衡毒性和制剂实施与依从性挑战。
局限性
- 研究基于3项研究的数据,样本量有限,且优化剂量需进一步验证毒性和实施可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis affects over one million children annually. Ethambutol (EMB) is a key component of first-line therapy, but comprehensive pediatric pharmacokinetic studies have been lacking. METHODS: EMB concentrations and individual-level patient data from 3 studies were analyzed using nonlinear mixed effects modeling. Simulations compared current World Health Organization (WHO)-recommended doses and model-informed optimized doses. Target exposure distribution (area under the curve, 13.8-17.7 mg·h/L), which had been previously established in adult clinical trials, guided dose optimization. RESULTS: A total of 220 participants (0.2-15 years; 3.6 and 43.0 kg) contributed 1085 plasma EMB concentrations for model development. Weight effects were incorporated for clearance (CL), intercompartmental CL, and volumes of distribution in central and peripheral compartments. Age affected CL through a maturation function. Simulations indicated children weighing <25 kg had median exposures below target exposure distribution at current WHO-recommended doses. Optimized weight-band dosing would increase doses in approximately 40.5% of the patients, with an additional 5% potentially benefiting. CONCLUSIONS: Our individual patient data meta-analysis supports the revision of current pediatric EMB dosing guidelines for the treatment of tuberculosis. Our findings aim to ensure adequate drug exposure across all pediatric weight bands, while also accounting for toxicity and challenges related to formulation implementation and adherence.
引用
- Chung TK, Yang E, Shin M, et al. Pharmacokinetics and Dose Optimization of Ethambutol in Children on First-Line Antituberculosis Therapy: An Individual Patient Data Meta-Analysis. J Infect Dis. 2026. PMID: 41906661. doi:10.1093/infdis/jiag194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。